Filing Flows

Filing Flows › Companies › Biocryst Pharmaceuticals › Cash flow

Biocryst Pharmaceuticals cash flow, quarter by quarter

Latest: Q3 2026 · from the cash-flow statements filed with the SEC

Free cash flow$32.8M in Q3 2026 · $366M over twelve months

Operating cash flow$33.0M
Capital spending−$233K
Free cash flow+$32.8M
Cash / net income0.9×
Cash conversion cycle-123 days

Analysis

In Q3 2026, Biocryst Pharmaceuticals generated $33.0M of operating cash flow and spent $233K on capital projects, leaving free cash flow of $32.8M. That is $7.5M less than in Q3 2025 ($40.3M).

Over the twelve months to Sep 30, 2026, operating cash flow was $367M; the largest uses were other investing ($540M), other financing ($61.4M), taxes on employees’ shares ($12.3M); besides operations, cash came from net borrowing (+) / repaid (−) ($214M), shares issued ($30.6M); the cash balance rose by $12.4M.

Operating cash flow was $33.0M against net income of $37.9M — 0.9× profit, less cash than reported earnings, worth checking against working capital. The largest differences: stock-based pay +$14.2M, receivables −$11.0M, payables +$9.7M.

Its cash conversion cycle was -123 days (receivables 59 + inventory 579 − payables 761): suppliers fund its working capital.

Free cash flow

Biocryst Pharmaceuticals: free cash flow by quarterBiocryst Pharmaceuticals: free cash flow by quarter−$5.9MQ4 2024−$27.7MQ1 2025$41.1MQ2 2025$40.3MQ3 2025$291MQ4 2025−$62.2MQ1 2026$104MQ2 2026$32.8MQ3 2026
Operating cash flow less capital spending.
Biocryst Pharmaceuticals: operating cash flow against capital spendingBiocryst Pharmaceuticals: operating cash flow against capital spendingOperating cash flowCapital spending−$5.2M$675KQ4 2024−$27.5M$143KQ1 2025$41.3M$179KQ2 2025$41.6M$1.3MQ3 2025$292M$802KQ4 2025−$61.8M$403KQ1 2026$104M$209KQ2 2026$33.0M$233KQ3 2026
Latest (Q3 2026): Operating cash flow $33.0M, Capital spending $233K.

Capital allocation, year by year

Biocryst Pharmaceuticals: where the cash came from (up) and went (down), by fiscal yearBiocryst Pharmaceuticals: where the cash came from (up) and went (down), by fiscal yearOperating cash flowNet borrowingShares issuedAsset salesCapital spendingFY2021: Operating cash flow −$142MFY2021: Shares issued $65.8MFY2021: Capital spending −$2.4M$65.8MFY2021FY2022: Operating cash flow −$162MFY2022: Net borrowing $73.1MFY2022: Shares issued $15.0MFY2022: Capital spending −$1.4M$88.0MFY2022FY2023: Operating cash flow −$95.1MFY2023: Net borrowing $58.4MFY2023: Shares issued $8.3MFY2023: Capital spending −$2.2M$66.7MFY2023FY2024: Operating cash flow −$52.0MFY2024: Net borrowing −$1.7MFY2024: Shares issued $3.4MFY2024: Capital spending −$1.1M$3.4MFY2024FY2025: Operating cash flow $347MFY2025: Net borrowing −$302MFY2025: Shares issued $9.1MFY2025: Asset sales −$6.2MFY2025: Capital spending −$2.5M$356MFY2025
Over these 5 years operating cash flow totalled −$104M; the largest uses were operating cash flow ($451M) and net borrowing ($304M). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$375M
Debt$396M
Net debt$20.6M

Biocryst Pharmaceuticals funds itself: free cash flow was $366M over the last twelve months, and $375M of cash and investments stands against $396M of debt.

Where the cash came from and went

Biocryst Pharmaceuticals: sources (+) and uses (−) of cash, Q3 2026Biocryst Pharmaceuticals: sources (+) and uses (−) of cash, Q3 2026Other investing−$78.6MCash drawn (+) / kept (−)$58.0MOperating cash flow$33.0MOther financing−$14.6MShares issued$4.2MTaxes on employees’ shares−$1.4MNet borrowing (+) / repaid (−)−$295KCapital spending−$233KExchange rates$6K
Biocryst Pharmaceuticals: sources (+) and uses (−) of cash, TTM to Q3 2026Biocryst Pharmaceuticals: sources (+) and uses (−) of cash, TTM to Q3 2026Other investing−$540MOperating cash flow$367MNet borrowing (+) / repaid (−)$214MOther financing−$61.4MShares issued$30.6MNot reconciled$14.8MCash drawn (+) / kept (−)−$12.4MTaxes on employees’ shares−$12.3MCapital spending−$1.6MExchange rates−$173K

From profit to cash

Biocryst Pharmaceuticals: net income to operating cash flow, Q3 2026Biocryst Pharmaceuticals: net income to operating cash flow, Q3 2026Net income$37.9MDepreciation & amortization$244KStock-based pay$14.2MReceivables−$11.0MInventory−$6.9MPayables$9.7MDeferred revenue−$3.6MPrepaid and other assets−$5.9MOperating cash flow$33.0M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.
QuarterReceivable daysInventory daysPayable daysCash conversion cycle
Q3 202659579761-123
Q2 202646143266-77
Q1 20266295224-67
Q4 20252251103-30
Q3 202553216298-29
Q2 202551194303-58
Q1 202553147214-13
Q4 202453118190-19

Every quarter

QuarterOperating cash flowCapital spendingAcquisitionsNet borrowing (+) / repaid (−)Shares issuedCash drawn (+) / kept (−)Free cash flow
Q3 2026$33.0M−$233K—−$295K$4.2M$58.0M$32.8M
Q2 2026$104M−$209K—−$361K$6.2M$17.0M$104M
Q1 2026−$61.8M−$403K−$489M$400M$19.5M−$82.0M−$62.2M
Q4 2025$292M−$802K—−$185M$657K−$5.3M$291M
Q3 2025$41.6M−$1.3M—−$46.9M$2.6M$3.9M$40.3M
Q2 2025$41.3M−$179K—−$536K$3.4M$17.0M$41.1M
Q1 2025−$27.5M−$143K—−$516K$2.4M−$558K−$27.7M
Q4 2024−$5.2M−$675K—−$356K−$586K−$7.3M−$5.9M

Biocryst Pharmaceuticals: income statement and cash flow

Biocryst Pharmaceuticals, Q3 2026: revenue $180M (+13% year over year), operating margin 29.6%. The chart follows the revenue to costs, profit and cash.

Biocryst Pharmaceuticals: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.